Kezar Life Sciences (NASDAQ:KZR) Stock Price Down 6.2%

Kezar Life Sciences, Inc. (NASDAQ:KZR)’s share price dropped 6.2% during mid-day trading on Monday . The stock traded as low as $0.80 and last traded at $0.81. Approximately 578,223 shares traded hands during mid-day trading, a decline of 19% from the average daily volume of 710,630 shares. The stock had previously closed at $0.86.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and issued a $20.00 target price on shares of Kezar Life Sciences in a research note on Friday, March 15th.

Kezar Life Sciences Stock Down 6.2 %

The company has a market cap of $58.93 million, a P/E ratio of -0.57 and a beta of 0.47. The company has a quick ratio of 11.66, a current ratio of 11.66 and a debt-to-equity ratio of 0.05. The business’s 50 day moving average is $0.90 and its 200 day moving average is $0.89.

Kezar Life Sciences (NASDAQ:KZR) last posted its quarterly earnings data on Thursday, March 14th. The company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.04. As a group, equities analysts anticipate that Kezar Life Sciences, Inc. will post -1.26 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Kezar Life Sciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in KZR. RVW Wealth LLC acquired a new stake in shares of Kezar Life Sciences during the third quarter worth $28,000. Amundi acquired a new stake in Kezar Life Sciences during the 4th quarter worth about $32,000. SG Americas Securities LLC purchased a new stake in Kezar Life Sciences during the 3rd quarter valued at about $39,000. Public Employees Retirement System of Ohio acquired a new position in shares of Kezar Life Sciences in the second quarter valued at about $45,000. Finally, Acadian Asset Management LLC purchased a new position in shares of Kezar Life Sciences in the first quarter worth about $45,000. 67.90% of the stock is currently owned by hedge funds and other institutional investors.

Kezar Life Sciences Company Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.